Linda Mpofu-Dobo

Mrs. Linda Mpofu-Dobo

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 June 2024 in Microorganisms
Verified
Journal Article
Open access
PDF file
MAMotswedi Anderson
Motswedi Anderson
TMThabo Mangogola
Thabo Mangogola
BPBonolo B. Phinius
Bonolo B. Phinius
GMGorata Goabaone Audrey Mpebe
Gorata Goabaone Audrey Mpebe
CAChristopher O. Aimakhu
Christopher O. Aimakhu
SGSimani Gaseitsiwe
Simani Gaseitsiwe
(1) Background: we determined the prevalence of the hepatitis B virus (HBV) amongst people without human immunodeficiency virus (HIV) in rural and peri-urban areas in Botswana. (2) Methods: We screened for the hepatitis B surface antigen (HBsAg) from archived plasma samples of people without HIV (n = 2135) randomly selected from the Botswana Combination Prevention Program (BCPP) (2013–2018). We sequenced 415 bp of the surface region using BigDye sequencing chemistry. (3) Results: The median age of participants was 31 (IQR: 24–46) and 64% (1360/2135) were female. HBV prevalence was 4.0% (86/2135) [95% CI: 3.3–4.9]) and ranged between 0–9.2%. Older participants (>35 years) had increased odds of HBV positivity (OR: 1.94; 95% CI: [1.32–2.86]; p = 0.001). Thirteen samples were sequenced and seven (53.8%) were genotype A, three (23.1%) were genotype D and genotype E each. Clinically significant mutations were identified in the surface region, but no classic drug resistance mutations were identified. (4) Conclusions: We report an HBV prevalence of 4.0% (95% CI 3.3–4.9) among people without HIV in rural and peri-urban communities in Botswana with varying rates in different communities. A comprehensive national HBV program is required in Botswana to guide HBV prevention, testing and management.

8 May 2024 in Preprints.org
Verified
Preprint
Open access
PDF file
MAMotswedi Anderson
Motswedi Anderson
TMThabo Mangogola
Thabo Mangogola
BPBonolo B. Phinius
Bonolo B. Phinius
GMGorata Goabaone Audrey Mpebe
Gorata Goabaone Audrey Mpebe
CAChristopher O. Aimakhu
Christopher O. Aimakhu
SGSimani Gaseitsiwe
Simani Gaseitsiwe
(1) Background: We determined the prevalence of hepatitis B virus (HBV) amongst people without human immunodeficiency virus (HIV) in rural and peri-urban areas in Botswana. (2) Methods: We screened hepatitis B surface antigen (HBsAg) from archived plasma samples of people without HIV (n=2135) randomly selected from the Botswana Combination Prevention Program (BCPP) (2013–2018). We sequenced 415 bp of the surface region using BigDye sequencing chemistry. (3) Results: The median age of participants was 31 (IQR: 24–46) and 64% (1360/2135) were female. HBsAg prevalence was 4.0% (86/2135) [95% CI: 3.3 – 4.9]) and ranged between 0%–9.2%. Older participants (>35 years) had increased odds of HBsAg positivity (OR: 1.94; 95% CI: [1.32–2.86]; p = 0.001. Thirteen samples were sequenced and 7 (53.8%) were genotype A, 3 (23.1%) were genotype D and genotype E each. Clinically significant mutations were identified in the surface region, but no classic drug resistance mutations were identified. (4) Conclusions: We report an HBV prevalence of 4.0% (95% CI 3.3 – 4.9) among people without HIV in rural and pe-ri-urban communities in Botswana with varying rates in different communities. A comprehen-sive national HBV program is required in Botswana to guide HBV prevention, testing and management.

17 August 2026 in Viruses
Verified
Journal Article
Open access
PDF file
TRTsholofelo Ratsoma
Tsholofelo Ratsoma
WCWonderful T Choga
Wonderful T Choga
FGFlorence G. Gaongalelwe
Florence G. Gaongalelwe
BPBonolo B. Phinius
Bonolo B. Phinius
GMGorata Goabaone Audrey Mpebe
Gorata Goabaone Audrey Mpebe
SGSimani Gaseitsiwe
Simani Gaseitsiwe
(1) Background: The Hepatitis B virus (HBV) is characterized by extensive genetic diversity, including low-frequency variants that contribute to disease progression. We aimed to characterize low-frequency variants and evaluate their potential clinical impact. (2) Methods: We utilized 104 HBV near-full-length sequences generated using next-generation sequencing (NGS) from people living with HIV (PLHIV). We used an in-house bioinformatics suite (HBVgenomeR v5.9.7) to filter for low-frequency variants (5–50%), which were compared to escape and drug resistance mutations (DRMs) and hepatocellular carcinoma (HCC)-associated mutations reported at the consensus level. Unclassified variants were characterized by HBV open reading frames (ORFs) to determine mutation frequency per genomic region. (3) Results: A total of six escape mutations were detected in 8/104 (7.7%) sequences, with surfaceN131T being the most prevalent (5/8). We also observed six DRMs in 30/104 (28.8%), with rtV173L being the most prevalent (21/30). Truncation mutations were also observed with rtA181T/sW172* and rtM204I/sW196L being the most prevalent. A total of 8/104 (7.7%) sequences had four variants associated with HCC. The xP46S was the highest observed HCC-associated mutation at 5/8. We report 1152 unique uncharacterized variants across all ORFs, and these were found in 94/104 (90.4%) sequences. The RNaseH domain had the highest burden (330/1152, 28.6%). (4) Conclusions: Deep sequencing results identified clinically significant mutations, including those below the 20% detection limit of traditional sequencing, that would go unreported. This highlights the possible underreporting of mutational burden in people living with HBV/HIV, indicating the importance of deep sequencing to aid in HBV/HIV understanding and management.

23 September 2026 in Genes
Verified
Journal Article
Open access
PDF file
CCColleague katlo Colleague
Colleague katlo Colleague
BPBonolo B. Phinius
Bonolo B. Phinius
KMKesaobaka Molebatsi
Kesaobaka Molebatsi
NKNametso Kelentse
Nametso Kelentse
LBLynnette Bhebhe
Lynnette Bhebhe
SGSimani Gaseitsiwe
Simani Gaseitsiwe
Background/Objectives: Increasing evidence suggests that the hepatitis B virus (HBV) can be detected in extrahepatic compartments. Data on the molecular characteristics of HBV in cerebrospinal fluid (CSF) remain limited, particularly among people living with HIV (PLWH) and cryptococcal meningitis (CM). This study aimed to characterize HBV genomes from plasma and CSF and compare paired sequences for genetic similarity and potential compartment-specific differences. Methods: Archived plasma and CSF samples from PLWH with CM from Botswana enrolled in AMBITION-CM trial (2018–2021) were sequenced using Oxford Nanopore Technology to generate near-full-length HBV genomes. Genotyping and mutational analysis were performed and paired plasma–CSF sequences were compared. Results: Four sequences were generated, including one plasma–CSF pair and two CSF-only sequences. The sequences clustered with genotypes A1 and D3. The single paired plasma–CSF sequences shared 98.8% nucleotide similarity, and clustered together with strong phylogenetic support (SH-aLRT/ultrafast bootstrap = 99.6/100). Variant analysis identified 492 and 545 high-quality variants (Q ≥ 30) in plasma and CSF, respectively. In the single paired sequences, hepatocellular carcinoma (HCC)-associated mutation T1858C was detected in plasma but not in the CSF. Mutations were also identified in CSF-derived sequences, including A1762T/G1764A, G1896A, G1899A, associated with increased HCC risk, rtS184L, rtF194L, rtP236T, linked to antiviral resistance and sP127L, sQ129L, sM133L, sS136P, associated with immune escape. Conclusions: Near-full-length HBV genomes were successfully recovered and genetically characterized from the CSF of PLWH with CM. The single plasma–CSF paired sample, showed high genetic similarity and had a compartment-specific mutation. Clinically relevant mutations were observed in the CSF warranting further investigation of HBV in the CSF to confirm these observations in PLWH with CM. These preliminary findings from a limited number of participants provide a basis for larger-scale studies of near-full-length HBV genome characterization in CSF.

30 April 2026 in Viruses
Verified
Journal Article
Open access
PDF file
LMLinda Mpofu-Dobo
Linda Mpofu-Dobo
KLKebaneilwe Lebani
Kebaneilwe Lebani
JBJason T Blackard
Jason T Blackard
SMSikhulile Moyo
Sikhulile Moyo
MAMotswedi Anderson
Motswedi Anderson
SGSimani Gaseitsiwe
Simani Gaseitsiwe
Hepatitis B virus (HBV) remains a leading cause of chronic liver disease worldwide, contributing to cirrhosis and hepatocellular carcinoma. Sub-Saharan Africa accounts for an estimated 68% of incident HBV infections, where co-infection with human immunodeficiency virus (HIV) is common and associated with poorer clinical outcomes. In Botswana, limited HBV screening and the absence of established HBV management guidelines persist despite reported HIV-HBV co-infection rates ranging from 1.1% to 10.6%. This scoping review aimed to summarise existing research on HBV and HIV-HBV co-infection in Botswana and assess clinical and policy implications. Following PRISMA methodology, searches were conducted across PubMed, Google Scholar, Semantic Scholar, and Consensus databases. Thirty eligible peer-reviewed studies were identified and evaluated for prevalence data, virological characteristics, genotypes, mutations, treatment outcomes, vaccination programs, and the availability of guidelines. Findings indicate intermediate-to-high HBV and HIV-HBV disease burden, substantial occult HBV infection, and gaps in diagnostic and preventive practices. The lack of routine screening, deficient infant birth-dose and adult vaccination, and established treatment pathways likely increase the risk of HBV-associated morbidity and mortality. Strengthened public health interventions, including expanded testing, enhanced vaccination coverage, and prevention of mother-to-child transmission strategies, are recommended to improve disease control and clinical outcomes in Botswana.